Get the latest public health information from CDC.
Get the latest research information from NIH. | Español
NCATS develops novel approaches to improve the process of joining basic science discoveries with initial testing of therapies in humans.
A team of researchers used organoids — tiny 3-D tissue models of human brain development — to better understand brain infections caused by SARS-CoV-2.
NCATS researchers, led by Ruili Huang, Ph.D., and Wei Zheng, Ph.D., develop an approach called biological activity-based modeling (BABM), which could speed the search for therapies for COVID-19 and other diseases.
Researchers from NCATS and the National Cancer Institute teamed up to identify and test different drug combinations against small cell lung cancer (SCLC).
Creating and testing innovative methods to improve and accelerate the drug development process and find new treatments for patients faster.
Discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
Developing better model systems for drug and toxicity testing.
Using state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Improving the Drug Development Process
Testing & Predictive Models
Work with Us
NCATS preclinical programs and resources focus on key obstacles and inefficiencies in the translational process, overcoming bottlenecks that slow the development of new treatments for patients.
Learn more about how to access NCATS programs and expertise.
Take a video tour of our labs and see firsthand how our researchers work to get more treatments to more patients more quickly.
Learn more about NCATS’ Achievements in Advancing Translational Sciences.
NCATS Programs & Resources Supporting Preclinical Innovation